Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Kirsten rat sarcoma virus (KRAS) is a prevalent oncogene in human cancers, notably non-small-cell lung cancer (NSCLC).
• KRAS mutations, especially KRAS-G12C, were historically challenging to target therapeutically.
• The identification of the switch II region in KRAS-G12C enabled the development of direct inhibitors.

Purpose of the Study:

• To review the fundamental biology and mutation characteristics of the KRAS protein.
• To summarize current and emerging therapeutic strategies for KRAS-mutated lung cancer.
• To discuss approaches for overcoming resistance to KRAS-targeted therapies.

Main Methods:

• Literature review of KRAS biology, mutation subtypes, and targeted therapies.
• Analysis of FDA-approved KRAS-G12C inhibitors (sotorasib, adagrasib).
• Examination of ongoing research into combination strategies and resistance mechanisms.

Main Results:

• KRAS-G12C inhibitors like sotorasib and adagrasib show efficacy in pre-treated NSCLC patients.
• Mechanisms of resistance limit the long-term effectiveness of current KRAS inhibitors.
• Combination therapies are under investigation to enhance treatment outcomes.

Conclusions:

• Targeting KRAS mutations, particularly KRAS-G12C, represents a significant advancement in NSCLC treatment.
• Overcoming resistance is crucial for maximizing the benefit of novel KRAS inhibitors.
• Personalized treatment strategies are essential for managing lung cancer with KRAS driver mutations.